HealthQuill Eli Lilly
Swiss healthcare multinational F. Hoffmann-La Roche AG will invest $50 billion in the US over the next five years to expand its research and manufacturing facilities.
Drugs Medical Pharma

Roche to invest $50 billion in US over next five years to expand capacity

HQ Team April 22, 2025: Swiss healthcare multinational F. Hoffmann-La Roche AG will invest $50 billion in the US over the next five.

Read More
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Pharma

Novartis bets $23b on US as pharma giants brace for tariff storm

Swati Mishra April 11, 2025: “We are prepared for shifts in the external environment and fully confident in our growth outlook,” Novartis CEO Vas.

Read More
Eli Lilly will set up four new pharmaceutical manufacturing facilities in the US for $27 billion to further bolster its supply chains, according to a statement.
Drugs Medical Pharma

Eli Lilly to set up four manufacturing facilities in US for $27 billion

Eli Lilly will set up four new pharmaceutical manufacturing facilities in the US for $27 billion to further bolster its supply chains, according.

Read More
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to a company statement.
Drugs Health Medical

Eli Lilly halts trials of investigational chronic kidney disease drug

Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to.

Read More
Eli Lilly's Omvah gains FDA approval for treating Crohn's disease
Drugs Health Medical

Eli Lilly’s Omvoh gains FDA approval for treating Crohn’s disease

HQ Team The US Food and Drug Administration (FDA) has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active.

Read More
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a statement.
Uncategorized

Novo Nordisk says its drug CargiSema cuts body weight by 22.7% in adults

Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.

Read More
The WHO says close to 18 million people die due to cardiovascular disease every year out of which maximum deaths are due to SCA. Heart attacks occur when there is a blockage in one or more of the arteries to the heart, preventing the heart from receiving enough oxygen-rich blood.
Pharma

Eli Lilly’s pill for genetic high cholesterol cuts risk by 86% in trial 2

HQ Team November 19, 2024: Eli Lilly announced promising results from its Phase 2 clinical trial of muvalaplin, an oral medication designed to.

Read More
obesity
Health

Lilly’s trial results for treating obesity and pre-diabetes are promising

HQ Team November 15, 2024: Eli Lilly’s Phase III trial has yielded positive results from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for.

Read More
Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat Alzheimer’s disease, diabetes and obesity, according to a company statement.
Drugs Health Pharma

Eli Lilly to invest $1b in Irish facility to make Alzheimer’s, obesity drugs

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat.

Read More
Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to 49 nations in Africa.
Drugs Health Pharma

Eli Lilly to license rheumatoid drug-making technology to Egypt’s EVA

Eli Lilly will license manufacturing know-how of its rheumatoid arthritis baricitinib drug, branded as Olumiant, to Egypt’s EVA Pharma to expand its access to.

Read More